TWST · Twist Bioscience Corporation
Twist Bioscience Corporation (TWST) manufactures and sells synthetic DNA-based products. The company is a supplier to genomics, synthetic biology, and bioengineering customers, positioning it as a picks-and-shovels play on growing demand for DNA synthesis, sequencing support, and lab automation.
Recent proof-backed thesis calls
Recent internal coverage referenced TWST in 'Big Ideas 2026: Multiomics' and in an interview/podcast featuring Colossal Biosciences CEO Ben Lamm on AI-enabled synthetic biology. These pieces are thematic and educational rather than direct company catalysts, highlighting demand drivers for sequencing, multi-layer biological data, and tools used across synthetic biology workflows.
Interview/podcast with Colossal Biosciences CEO Ben Lamm discussing AI-enabled synthetic biology, de-extinction, biodiversity preservation, plastic pollution solutions, and “living products.” Colossal is private, and the content appears promotional/educational rather than a public-company news catalyst. Public-market relevance is mainly thematic for synthetic biology, genomics tools, sequencing, lab automation, and AI-drug-discovery names.
ARK’s Big Ideas 2026 (Multiomics) segment outlines the investment case for “multiomics” (integrating genomics, transcriptomics, proteomics, etc.) as biology moves from single-layer measurement to multi-layer data + computation. The talk highlights downstream implications across (1) data generation (sequencing/single-cell/proteomics platforms), (2) diagnostics (earlier, cheaper, more precise testing), (3) drug development (better target ID/stratification), and (4) therapeutics (more precise, pote
Latest market-close explanation
On 2026-04-13 TWST closed up 5.16% at $50.38 (prior close $47.91), intraday range $47.56–$50.69, and volume +35.1% vs. the prior session. Internal coverage also referenced 'Big Ideas 2026: Multiomics.'
**TWST** (Twist Bioscience Corporation) moved **+5.16%** on 2026-04-13, closing at **$50.38** after a previous close of **$47.91**. Intraday range was **$47.56** to **$50.69**. Volume changed **+35.1%** versus the prior session. Recent internal coverage also touched TWST: **Big Ideas 2026: Multiomics**.
Current stance
No active buy/sell recommendation is listed. Coverage in our research is thematic: Twist is relevant as a supplier to genomic and synthetic biology workflows but not identified as having a new company-specific catalyst in the cited materials.
- beneficiary via AI + synthetic biology remains a long-term thematic basket rather than a near-term catalyst from this source. from https://www.youtube.com/@peterdiamandis (confidence 0.24)
Top authors on this asset
Active and historical ticker theses
Active play: 'AI + Synthetic Biology' — positions companies like TWST as picks-and-shovels suppliers to the long-term theme of AI-enabled synthetic biology. The play notes broad, long-term transformational potential rather than immediate near-term catalysts.
Unlock full asset monitoring
For investors: monitor sequencing and synthetic biology demand signals, multiomics adoption, and company-specific execution (revenue mix, gross margins, customer concentration). The cited content is thematic — check company disclosures for any material, company-specific news.